HRP20211942T1 - Medicinska uporaba 5'-adenozin difosfat riboze (adpr) - Google Patents
Medicinska uporaba 5'-adenozin difosfat riboze (adpr) Download PDFInfo
- Publication number
- HRP20211942T1 HRP20211942T1 HRP20211942TT HRP20211942T HRP20211942T1 HR P20211942 T1 HRP20211942 T1 HR P20211942T1 HR P20211942T T HRP20211942T T HR P20211942TT HR P20211942 T HRP20211942 T HR P20211942T HR P20211942 T1 HRP20211942 T1 HR P20211942T1
- Authority
- HR
- Croatia
- Prior art keywords
- adpr
- adenosine diphosphate
- patient
- diphosphate ribose
- use according
- Prior art date
Links
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 title claims 12
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 title claims 12
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 title claims 12
- 238000000034 method Methods 0.000 title claims 4
- PWJFNRJRHXWEPT-AOOZFPJJSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3r,4r)-2,3,4-trihydroxy-5-oxopentyl] hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O)[C@@H](O)[C@H]1O PWJFNRJRHXWEPT-AOOZFPJJSA-N 0.000 claims 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 239000012453 solvate Substances 0.000 claims 8
- SMBQBQBNOXIFSF-UHFFFAOYSA-N dilithium Chemical class [Li][Li] SMBQBQBNOXIFSF-UHFFFAOYSA-N 0.000 claims 7
- 238000001802 infusion Methods 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 206010023332 keratitis Diseases 0.000 claims 4
- 241000701161 unidentified adenovirus Species 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000001413 cellular effect Effects 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 210000002345 respiratory system Anatomy 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 2
- 201000007100 Pharyngitis Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 208000019155 Radiation injury Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical group [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims 2
- 229910003002 lithium salt Inorganic materials 0.000 claims 2
- 159000000002 lithium salts Chemical class 0.000 claims 2
- 229910052751 metal Chemical class 0.000 claims 2
- 239000002184 metal Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 1
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical class NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 206010010984 Corneal abrasion Diseases 0.000 claims 1
- 208000028006 Corneal injury Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 241000792859 Enema Species 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 201000008197 Laryngitis Diseases 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010028116 Mucosal inflammation Diseases 0.000 claims 1
- 201000010927 Mucositis Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010068319 Oropharyngeal pain Diseases 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010044302 Tracheitis Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 229960004150 aciclovir Drugs 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 238000012387 aerosolization Methods 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010217 blepharitis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 229960000724 cidofovir Drugs 0.000 claims 1
- 229910017052 cobalt Inorganic materials 0.000 claims 1
- 239000010941 cobalt Substances 0.000 claims 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 239000012738 dissolution medium Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000007920 enema Substances 0.000 claims 1
- 229940079360 enema for constipation Drugs 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 229960002963 ganciclovir Drugs 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 1
- 239000008263 liquid aerosol Substances 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 239000004530 micro-emulsion Substances 0.000 claims 1
- 239000007908 nanoemulsion Substances 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 206010033072 otitis externa Diseases 0.000 claims 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- JJICLMJFIKGAAU-UHFFFAOYSA-M sodium;2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)purin-6-olate Chemical class [Na+].NC1=NC([O-])=C2N=CN(COC(CO)CO)C2=N1 JJICLMJFIKGAAU-UHFFFAOYSA-M 0.000 claims 1
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical class [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 208000025889 stromal keratitis Diseases 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 206010044008 tonsillitis Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 210000001835 viscera Anatomy 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Claims (14)
1. 5'-adenozin difosfat riboza (ADPR), ili njegova farmaceutski prihvatljiva sol, solvat, hidrat, tautomer, stereoizomer, izotopol, ili polimorf za uporabu u postupku liječenja, upravljanja, ili prevenciju bolesti ili stanja povezanih s adenovirusom kod pacijenta, navedeni postupak sadrži davanje pacijentu učinkovite količine 5'-adenozin difosfat riboze (ADPR), ili njegove farmaceutski prihvatljive soli, solvata, hidrata, tautomera, stereoizomera, izotopologa ili polimorfa; pri čemu pacijent ima ili je u opasnosti od razvoja bolesti ili stanja povezanog s adenovirusom.
2. 5'-adenozin difosfat riboza (ADPR) za uporabu prema zahtjevu 1, naznačena time što je bolest ili stanje povezano s adenovirusom bolest ili stanje koje zahvaća bilo koji dio oka, uha, usta, gornjih dišnih puteva ili donjeg respiratornog trakta.
3. 5'-adenozin difosfat riboza (ADPR) za uporabu prema zahtjevu 1, naznačena time što je bolest ili stanje povezano s adenovirusom epibulbarna bolest, konjuktivitis, keratitis, kerato-konjunktivitis, abrazija rožnice, ulcerozni infektivni keratitis, epitelni keratitis, stromalni keratitis, uveitis, akutni glaukom, blefaritis, otitis media, otitis eksterna, gingivitis, mukozitis, faringitis, tonzilitis, rinitis, sinusitis, laringitis, grlobolja, traheitis, bronhitis, bronhiolitis, bronhiolarna upala pluća, upala pluća, pogoršanje astme, pogoršanje kronične opstruktivne plućne bolesti ili pogoršanje emfizema.
4. 5'-adenozin difosfat riboza (ADPR) za uporabu prema zahtjevu 1, naznačena time što se primjena vrši lokalnom, oralnom, parenteralnom, mukoznom, inhalacijskom primjenom, intravenskom, intra-arterijskom, ili intraduktalnom infuzijom.
5. 5'-adenozin difosfat riboza (ADPR) za uporabu prema zahtjevu 1, naznačena time što se primjena vrši lokalnom primjenom, pri čemu je navedena lokalna primjena:
a. unutarnja stanična ili tkivna površina pacijenta; ili
b. vanjska stanična ili tkivna površina, izborno pri čemu vanjska stanična ili tkivna površina je površina kože, oka, nokta, kose, ili uha.
6. 5'-adenozin difosfat riboza (ADPR) za uporabu prema zahtjevu 5(a), pri čemu se lokalna primjena vrši putem:
a. aerosolizacije, spreja, oralne primjene, intra-trahealne infuzije, intra-bronhijalne, ili infuzije na površinu respiratornog trakta;
b. oralne primjene, infuzije, ili klistira na površinu gastrointestinalnog trakta; ili
c. parenteralne injekcije ili infuzije u unutarnji organ.
7. 5'-adenozin difosfat riboza (ADPR) za uporabu prema zahtjevu 1, naznačena time što je ADPR u obliku otopine, suspenzije, emulzije, mikroemulzije, nanoemulzije, sirupa, eliksira, aerosola suhog praha, tekućeg aerosola, tablete, ili medija za otapanje, poželjno pri čemu je medij za otapanje brzo-otapajuća tableta, film, ili traka.
8. 5'-adenozin difosfat riboza (ADPR) za uporabu prema bilo kojem od zahtjeva 1-7, naznačena time što se ADPR primjenjuje u kombinaciji s drugim lijekom, poželjno gdje je drugi lijek antivirusni spoj, cidofovir, aciklovir, ganciklovir ili metalna sol.
9. 5'-adenozin difosfat riboza (ADPR) za uporabu prema zahtjevu 8, naznačena time što metalna sol je sol litija, cinka, kobalta, ili bakra, izborno pri čemu je litijeva sol litijev klorid.
10. 5'-adenozin difosfat riboza (ADPR) za uporabu prema zahtjevu 1, naznačen time što je ADPR u obliku njegove natrijeve soli, litijeve soli ili dilitijeve soli.
11. Spoj koji ima formulu:
[image]
ili njihov solvat, hidrat, tautomer, stereoizomer, izotopolog, ili polimorf.
12. Farmaceutski pripravak koji sadrži (i) dilitijev ADPR, ili njegov solvat, hidrat, tautomer, stereoizomer, izotopolog, ili polimorf, i (ii) jedan ili više farmaceutski prihvatljivih ekscipijenata; pri čemu je količina dilitijevog ADPR-a u farmaceutskom pripravku u rasponu od oko 0.001% w/w do oko 10% w/w farmaceutskog pripravka.
13. Dilitijev ADPR, ili njegov solvat, hidrat, tautomer, stereoizomer, izotopolog, ili polimorf za uporabu u postupku liječenja, upravljanja, ili prevenciju raka kod pacijenta, navedeni postupak sadrži davanje pacijentu učinkovite količine dilitijevog ADPR-a, ili njegovog solvata, hidrata, tautomera, stereoizomera, izotopologa, ili polimorfa; pri čemu pacijent ima ili je u opasnosti od razvoja raka, poželjno pri čemu je rak rak pluća, adenokarcinom pluća, karcinom pluća nemalih stanica, rak gušterače, adenokarcinom gušterače, gliom, multiformni glioblastom, ili akutna mijeloična leukemija.
14. Dilitijev ADPR, ili njegov solvat, hidrat, tautomer, stereoizomer, izotopolog, ili polimorf za uporabu u postupku liječenja, upravljanja, ili prevenciju poremećaja oka ili bolesti ili stanja uzrokovanog infekcijom, upalom ili fizičkom, kemijskom, toplinskom, ili ozljedom zračenja kod pacijenta, navedeni postupak sadrži davanje pacijentu učinkovite količine dilitijevog ADPR-a, ili njegovog solvata, hidrata, tautomera, stereoizomera, izotopologa, ili polimorfa; pri čemu pacijent ima ili je u opasnosti od razvoja poremećaja oka ili bolesti ili stanja uzrokovanog infekcijom, upalom, ili fizičkom, kemijskom, toplinskom, ili ozljedom zračenja.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662296665P | 2016-02-18 | 2016-02-18 | |
| US201662428721P | 2016-12-01 | 2016-12-01 | |
| PCT/US2017/018253 WO2017143113A1 (en) | 2016-02-18 | 2017-02-17 | Methods for the use of 5'-adenosine diphosphate ribose (adpr) |
| EP17708104.9A EP3416654B1 (en) | 2016-02-18 | 2017-02-17 | Medical use of 5'-adenosine diphosphate ribose (adpr) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211942T1 true HRP20211942T1 (hr) | 2022-03-18 |
Family
ID=58191671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211942TT HRP20211942T1 (hr) | 2016-02-18 | 2017-02-17 | Medicinska uporaba 5'-adenozin difosfat riboze (adpr) |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11110112B2 (hr) |
| EP (2) | EP3978003A1 (hr) |
| JP (3) | JP6946353B2 (hr) |
| KR (2) | KR20230148389A (hr) |
| CN (2) | CN117482102A (hr) |
| AU (2) | AU2017219878B2 (hr) |
| BR (1) | BR112018016398A2 (hr) |
| CA (1) | CA3014071A1 (hr) |
| DK (1) | DK3416654T3 (hr) |
| ES (1) | ES2900524T3 (hr) |
| HR (1) | HRP20211942T1 (hr) |
| HU (1) | HUE057052T2 (hr) |
| IL (2) | IL261095B (hr) |
| LT (1) | LT3416654T (hr) |
| PL (1) | PL3416654T3 (hr) |
| PT (1) | PT3416654T (hr) |
| WO (1) | WO2017143113A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117482102A (zh) | 2016-02-18 | 2024-02-02 | 伊维萨股份有限公司 | 使用5′-腺苷二磷酸核糖(adpr)的方法 |
| WO2019191026A2 (en) * | 2018-03-27 | 2019-10-03 | Invirsa, Inc. | Methods for the use of 5'-adenosine diphosphate ribose (adpr) |
| KR20230036274A (ko) | 2021-09-07 | 2023-03-14 | 정근영 | 방사선 및/또는 항암 치료 보조 요법으로 아데노신 디포스페이트 리보오스의 활용 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0618214A1 (en) | 1993-04-01 | 1994-10-05 | Merrell Dow Pharmaceuticals Inc. | Unsaturated phosphonate derivatives of purines and pyrimidines |
| JPH07247210A (ja) | 1994-03-09 | 1995-09-26 | Sunstar Inc | 口腔用組成物 |
| CA2302687A1 (en) * | 1997-09-11 | 1999-03-18 | Oxigene, Inc. | Uses of nicotinamide adenine dinucleotide and its analogs for treatment of malignant and infectious diseases |
| AR023088A1 (es) | 1999-02-26 | 2002-09-04 | Inspire Pharmaceuticals Inc | Uso de disfosfatos de uridina, adenina y citidina y analogos de los mismos para la manufactura de un medicamento para la estimulacion de la hidratacion delas mucosas. |
| AU779689B2 (en) | 1999-06-16 | 2005-02-03 | Icos Corporation | Human poly(ADP-ribose) polymerase 2 materials and methods |
| US6528042B1 (en) | 1999-10-08 | 2003-03-04 | Galileo Laboratories, Inc. | Compositions of flavonoids for use as cytoprotectants and methods of making and using them |
| US7115585B2 (en) | 2000-08-21 | 2006-10-03 | Inspire Pharmaceuticals, Inc. | Compositions for treating epithelial and retinal tissue diseases |
| WO2003011885A1 (en) | 2001-07-25 | 2003-02-13 | Celltech R & D Limited | Non-natural carbon-linked nucleotides and dinucleotides |
| ATE417616T1 (de) | 2002-05-21 | 2009-01-15 | Abbott Lab | Behandlung von mukositis |
| US20070212395A1 (en) | 2006-03-08 | 2007-09-13 | Allergan, Inc. | Ocular therapy using sirtuin-activating agents |
| US20050276762A1 (en) | 2004-06-15 | 2005-12-15 | Tapas Das | Topical compositions containing 5'-adenosine-diphosphate ribose |
| AU2006249816A1 (en) | 2005-05-25 | 2006-11-30 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| JP5221368B2 (ja) | 2005-11-14 | 2013-06-26 | サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク（セエヌエールエス） | Ｐａｒｐ活性のインヒビター及びその使用 |
| WO2008154129A1 (en) | 2007-06-08 | 2008-12-18 | Bausch & Lomb Incorporated | Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye |
| US20110217262A1 (en) | 2010-03-05 | 2011-09-08 | Kornfield Julia A | Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability |
| AU2011251622A1 (en) | 2010-05-10 | 2012-12-20 | Radikal Therapeutics Inc. | Lipoic acid and nitroxide derivatives and uses thereof |
| US20150038473A1 (en) | 2011-05-12 | 2015-02-05 | Foresight Biotherapeutics, Inc. | Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories |
| WO2015073319A1 (en) | 2013-11-18 | 2015-05-21 | Massachusetts Institute Of Technology | Compositions and methods for treating immune and viral disorders and modulating protein-rna interaction |
| CN117482102A (zh) | 2016-02-18 | 2024-02-02 | 伊维萨股份有限公司 | 使用5′-腺苷二磷酸核糖(adpr)的方法 |
| WO2019191026A2 (en) | 2018-03-27 | 2019-10-03 | Invirsa, Inc. | Methods for the use of 5'-adenosine diphosphate ribose (adpr) |
-
2017
- 2017-02-17 CN CN202311353882.5A patent/CN117482102A/zh active Pending
- 2017-02-17 EP EP21198288.9A patent/EP3978003A1/en active Pending
- 2017-02-17 LT LTEPPCT/US2017/018253T patent/LT3416654T/lt unknown
- 2017-02-17 JP JP2018563379A patent/JP6946353B2/ja active Active
- 2017-02-17 HU HUE17708104A patent/HUE057052T2/hu unknown
- 2017-02-17 CA CA3014071A patent/CA3014071A1/en active Pending
- 2017-02-17 PL PL17708104T patent/PL3416654T3/pl unknown
- 2017-02-17 HR HRP20211942TT patent/HRP20211942T1/hr unknown
- 2017-02-17 EP EP17708104.9A patent/EP3416654B1/en active Active
- 2017-02-17 KR KR1020237034890A patent/KR20230148389A/ko active Application Filing
- 2017-02-17 WO PCT/US2017/018253 patent/WO2017143113A1/en active Application Filing
- 2017-02-17 PT PT177081049T patent/PT3416654T/pt unknown
- 2017-02-17 AU AU2017219878A patent/AU2017219878B2/en active Active
- 2017-02-17 KR KR1020187022959A patent/KR102622656B1/ko active IP Right Grant
- 2017-02-17 CN CN201780011126.0A patent/CN108601793A/zh active Pending
- 2017-02-17 BR BR112018016398A patent/BR112018016398A2/pt not_active Application Discontinuation
- 2017-02-17 DK DK17708104.9T patent/DK3416654T3/da active
- 2017-02-17 ES ES17708104T patent/ES2900524T3/es active Active
- 2017-02-17 US US15/999,269 patent/US11110112B2/en active Active
-
2018
- 2018-08-10 IL IL261095A patent/IL261095B/en unknown
-
2021
- 2021-08-03 US US17/392,578 patent/US11857561B2/en active Active
- 2021-09-15 JP JP2021149881A patent/JP7222042B2/ja active Active
-
2022
- 2022-03-21 IL IL291574A patent/IL291574A/en unknown
-
2023
- 2023-02-02 JP JP2023014497A patent/JP2023055858A/ja active Pending
- 2023-03-17 AU AU2023201678A patent/AU2023201678A1/en active Pending
- 2023-11-07 US US18/503,967 patent/US20240091249A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102622656B1 (ko) | 2024-01-10 |
| US11857561B2 (en) | 2024-01-02 |
| JP2019505596A (ja) | 2019-02-28 |
| IL261095B (en) | 2022-04-01 |
| KR20230148389A (ko) | 2023-10-24 |
| JP7222042B2 (ja) | 2023-02-14 |
| IL261095A (en) | 2018-10-31 |
| CN108601793A (zh) | 2018-09-28 |
| WO2017143113A1 (en) | 2017-08-24 |
| PT3416654T (pt) | 2021-12-22 |
| US11110112B2 (en) | 2021-09-07 |
| JP2023055858A (ja) | 2023-04-18 |
| AU2017219878B2 (en) | 2022-12-22 |
| BR112018016398A2 (pt) | 2018-12-18 |
| IL291574A (en) | 2022-05-01 |
| EP3416654A1 (en) | 2018-12-26 |
| EP3416654B1 (en) | 2021-10-27 |
| JP6946353B2 (ja) | 2021-10-06 |
| US20220054522A1 (en) | 2022-02-24 |
| DK3416654T3 (da) | 2021-12-13 |
| KR20180111841A (ko) | 2018-10-11 |
| ES2900524T3 (es) | 2022-03-17 |
| CN117482102A (zh) | 2024-02-02 |
| AU2023201678A1 (en) | 2023-04-13 |
| LT3416654T (lt) | 2022-01-10 |
| JP2021193126A (ja) | 2021-12-23 |
| US20200330498A1 (en) | 2020-10-22 |
| PL3416654T3 (pl) | 2022-03-21 |
| EP3978003A1 (en) | 2022-04-06 |
| US20240091249A1 (en) | 2024-03-21 |
| HUE057052T2 (hu) | 2022-04-28 |
| AU2017219878A1 (en) | 2018-08-09 |
| CA3014071A1 (en) | 2017-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6392241B2 (ja) | ３，５−ジアミノ−６−クロロ−ｎ−（ｎ−（４−フェニルブチル）カルバムイミドイル）ピラジン−２−カルボキサミド化合物 | |
| JP6392242B2 (ja) | 粘膜への水分付与が不十分であることが好都合である疾患の治療に有用なクロロ−ピラジンカルボキサミド誘導体 | |
| HRP20211942T1 (hr) | Medicinska uporaba 5'-adenozin difosfat riboze (adpr) | |
| ES2553788T3 (es) | 3,5-diamino-6-cloro-N-(N-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazino-2-carboxamida | |
| JP2021098728A5 (hr) | ||
| ES2802175T3 (es) | Tieno [3,2-d]pirimidinas, furo[3,2,d]pirimidinas y pirrolo[3,2-d]pirimidinas útiles para el tratamiento de infecciones del virus sincitial respiratorio | |
| ES2717898T3 (es) | Efecto potenciador para agentes antitumorales | |
| JP2014518268A5 (hr) | ||
| JP2015529234A5 (hr) | ||
| RU2018126793A (ru) | Тетрагидропиранил амино-пирролопиримидинон и способы его применения | |
| ES2825700T3 (es) | Derivados de pirimidina sustituidos útiles en el tratamiento de enfermedades autoinmunitarias | |
| JP2023071933A5 (hr) | ||
| JP2018197263A (ja) | アリールアルキル及びアリールオキシアルキル置換の上皮ナトリウムチャネル遮断化合物 | |
| ES2949441T3 (es) | Métodos para el uso de 5'-adenosina difosfato ribosa (ADPR) | |
| US20220193106A1 (en) | Nucleobase analogue derivatives and their applications | |
| HRP20210040T1 (hr) | (2r,4r)-5-(5′-klor-2’-fluorbifenil-4-il)-2-hidroksi-4-[(5-metiloksazol-2-karbonil)amino]pentanska kiselina | |
| JP2019505596A5 (hr) | ||
| WO2014152733A1 (en) | A method of providing ocular neuroprotection | |
| JP2022169780A5 (hr) | ||
| ES2945865T3 (es) | Combinación de un derivado de 6-oxo-1,6-dihidropiridazina que tiene actividad anticancerígena con un derivado de quinazolina | |
| JPWO2019191026A5 (hr) | ||
| ES2887426T3 (es) | Lenvatinib combinado con etopósido e ifosfamida para su uso en el tratamiento de un tumor |